(Q35128911)

6 August 2017

1 reference

title

Such stuff as dreams are made on: mediator-directed therapy in sepsis (English)

1 reference

6 August 2017

0 references

1 reference

3 January 2024

author name string

John C. Marshall

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12750742

3 January 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12750742

3 January 2024

publication date

1 May 2003

1 reference

full work available at URL

6 August 2017

https://www.nature.com/articles/nrd1084.pdf

file format

Portable Document Format

1 reference

https://www.nature.com/articles/nrd1084

3 January 2024

1 reference

Nature Reviews Drug Discovery

3 January 2024

published in

1 reference

6 August 2017

volume

2

1 reference

6 August 2017

issue

5

1 reference

6 August 2017

page(s)

391-405

1 reference

Sepsis and controlled clinical trials: the odyssey continues

6 August 2017

cites work

1 reference

Sepsis research: we must change course

31 March 2020

1 reference

Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care

31 March 2020

1 reference

Efficacy and safety of recombinant human activated protein C for severe sepsis

31 March 2020

1 reference

Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock

31 March 2020

1 reference

The Primary Role of Lymphoreticnlar Cells in the Mediation of Host Responses to Bacterial Endotoxim

31 March 2020

1 reference

Defective LPS Signaling in C3H/HeJ and C57BL/10ScCr Mice: Mutations in Tlr4 Gene

31 March 2020

1 reference

Toll signaling pathways in the innate immune response

31 March 2020

1 reference

HMG-1 as a late mediator of endotoxin lethality in mice

31 March 2020

1 reference

Association between mitochondrial dysfunction and severity and outcome of septic shock

31 March 2020

1 reference

Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans

31 March 2020

1 reference

Rapid onset of intestinal epithelial and lymphocyte apoptotic cell death in patients with trauma and shock

31 March 2020

1 reference

Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin

31 March 2020

1 reference

Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia

31 March 2020

1 reference

Human endothelial cell response to gram-negative lipopolysaccharide assessed with cDNA microarrays

31 March 2020

1 reference

A genomic and proteomic analysis of activation of the human neutrophil by lipopolysaccharide and its mediation by p38 mitogen-activated protein kinase.

31 March 2020

1 reference

Brief report: shock and multiple-organ dysfunction after self-administration of Salmonella endotoxin

31 March 2020

1 reference

Endotoxemia after major vascular operations

31 March 2020

1 reference

Intestinal permeability, gastric intramucosal pH, and systemic endotoxemia in patients undergoing cardiopulmonary bypass.

31 March 2020

1 reference

Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli

31 March 2020

1 reference

Prevention of gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid.

31 March 2020

1 reference

Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group

31 March 2020

1 reference

Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group.

31 March 2020

1 reference

Multicenter evaluation of a human monoclonal antibody to Enterobacteriaceae common antigen in patients with Gram-negative sepsis

31 March 2020

1 reference

Bactericidal/permeability-increasing protein (BPI) in sepsis correlates with the severity of sepsis and the outcome

31 March 2020

1 reference

Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group

31 March 2020

1 reference

Effect of the antiendotoxic agent, taurolidine, in the treatment of sepsis syndrome: a placebo-controlled, double-blind trial.

31 March 2020

1 reference

E5531, a pure endotoxin antagonist of high potency

31 March 2020

1 reference

Intravenous immunoglobulin for prophylaxis and therapy of sepsis

31 March 2020

1 reference

Signal transduction by tumor necrosis factor: the Parker B. Francis Lectureship

31 March 2020

1 reference

Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever

31 March 2020

1 reference

Activation of coagulation after administration of tumor necrosis factor to normal subjects

31 March 2020

1 reference

Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans

31 March 2020

1 reference

Plasma concentrations of cytokines, their soluble receptors, and antioxidant vitamins can predict the development of multiple organ failure in patients at risk.

31 March 2020

1 reference

Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients

31 March 2020

1 reference

Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group

31 March 2020

1 reference

Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases

31 March 2020

1 reference

Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group

31 March 2020

1 reference

CDP571, a humanized antibody to human tumor necrosis factor-alpha

31 March 2020

1 reference

Effect of a chimeric antibody to tumor necrosis factor-alpha on cytokine and physiologic responses in patients with severe sepsis--a randomized, clinical trial.

31 March 2020

1 reference

Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.

31 March 2020

1 reference

INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group.

31 March 2020

1 reference

Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group

31 March 2020

1 reference

Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study.

31 March 2020

1 reference

A multicenter, open-label, prospective, randomized, dose-ranging pharmacokinetic study of the anti-TNF-alpha antibody afelimomab in patients with sepsis syndrome

31 March 2020

1 reference

Interleukin 1 receptor antagonist. A new member of the interleukin 1 family

31 March 2020

1 reference

Antiinflammatory properties of hepatic acute phase proteins: preferential induction of interleukin 1 (IL-1) receptor antagonist over IL-1 beta synthesis by human peripheral blood mononuclear cells

31 March 2020

1 reference

Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial

31 March 2020

1 reference

Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group

31 March 2020

1 reference

Lipid mediators in the pathophysiology of critical illness

31 March 2020

1 reference

31 March 2020

1 reference

Mammalian secreted phospholipases A2 and their pathophysiological significance in inflammatory diseases

31 March 2020

1 reference

An update on inhibitors of human 14 kDa Type II s-PLA2 in development

31 March 2020

1 reference

The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis

31 March 2020

1 reference

Treatment with the platelet-activating factor antagonist TCV-309 in patients with severe systemic inflammatory response syndrome: a prospective, multi-center, double-blind, randomized phase II trial

31 March 2020

1 reference

Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group

31 March 2020

1 reference

Decreased organ failure in patients with severe SIRS and septic shock treated with the platelet-activating factor antagonist TCV-309: a prospective, multicenter, double-blind, randomized phase II trial. TCV-309 Septic Shock Study Group

31 March 2020

1 reference

A double-blind placebo-controlled study of an infusion of lexipafant (Platelet-activating factor receptor antagonist) in patients with severe sepsis.

31 March 2020

1 reference

Phase II multicenter clinical study of the platelet-activating factor receptor antagonist BB-882 in the treatment of sepsis

31 March 2020

1 reference

Randomized, double-blind phase II trial of Lexipafant, a platelet-activating factor antagonist, in human acute pancreatitis

31 March 2020

1 reference

Double blind, randomised, placebo controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis

31 March 2020

1 reference

Anti-inflammatory properties of a platelet-activating factor acetylhydrolase

31 March 2020

1 reference

The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group

31 March 2020

1 reference

Prostacyclin and thromboxane A2 formation is increased in human sepsis syndrome. Effects of cyclooxygenase inhibition

31 March 2020

1 reference

An open-label dose escalation study of the nitric oxide synthase inhibitor, N(G)-methyl-L-arginine hydrochloride (546C88), in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group.

31 March 2020

1 reference

Effect of L-NAME, an inhibitor of nitric oxide synthesis, on plasma levels of IL-6, IL-8, TNF alpha and nitrite/nitrate in human septic shock.

31 March 2020

1 reference

Methylene blue administration in septic shock: a clinical trial.

31 March 2020

1 reference

Use of methylene blue in patients with refractory septic shock: impact on hemodynamics and gas exchange

31 March 2020

1 reference

The pathophysiology and treatment of sepsis

31 March 2020

1 reference

Sir Isaac Newton, sepsis, SIRS, and CARS

31 March 2020

1 reference

Monocyte deactivation in septic patients: restoration by IFN-gamma treatment

31 March 2020

1 reference

Granulocyte colony-stimulating factor and modulation of inflammatory cells in sepsis

31 March 2020

1 reference

The Effects of Granulocyte Colony-Stimulating Factor (G-CSF) in Pre-Clinical Models of Infection and Acute Inflammation

31 March 2020

1 reference

Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial.

31 March 2020

1 reference

A randomized controlled trial of filgrastim as an adjunct to antibiotics for treatment of hospitalized patients with community-acquired pneumonia. CAP Study Group.

31 March 2020

1 reference

A randomized controlled trial of filgrastim for the treatment of hospitalized patients with multilobar pneumonia

31 March 2020

1 reference

Filgrastim (RHG-CSF) related modulation of the inflammatory response in patients at risk of sepsis or with sepsis

31 March 2020

1 reference

Filgrastim in patients with pneumonia and severe sepsis or septic shock

31 March 2020

1 reference

Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis

31 March 2020

1 reference

Regulation of tissue factor gene expression in the monocyte procoagulant response to endotoxin

31 March 2020

1 reference

Possible involvement of cytokines in diffuse intravascular coagulation and thrombosis

31 March 2020

1 reference

Integrin engagement induces monocyte procoagulant activity and tumor necrosis factor production via induction of tyrosine phosphorylation

31 March 2020

1 reference

31 March 2020

The protein C pathway

1 reference

Use of protein-C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans

31 March 2020

1 reference

Replacement therapy with protein C concentrate in infants and adolescents with meningococcal sepsis and purpura fulminans.

31 March 2020

1 reference

Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis

31 March 2020

1 reference

Therapeutic rationale for antithrombin III in sepsis

31 March 2020

1 reference

Thrombin induces NO release from cultured rat microglia via protein kinase C, mitogen-activated protein kinase, and NF-kappa B

31 March 2020

1 reference

Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies

31 March 2020

1 reference

Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis

31 March 2020

1 reference

Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial

31 March 2020

1 reference

Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis

31 March 2020

1 reference

Pharmacodynamics of active site-inhibited factor VIIa in endotoxin-induced coagulation in humans

31 March 2020

1 reference

Low-dose heparin for severe sepsis

31 March 2020

1 reference

Cortisol response to corticotropin and survival in septic shock

31 March 2020

1 reference

A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin

31 March 2020

1 reference

Corticosteroid therapy in severe illness

31 March 2020

1 reference

Steroids in the treatment of clinical septic shock

31 March 2020

1 reference

The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study

31 March 2020

1 reference

Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis

31 March 2020

1 reference

Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature.

31 March 2020

1 reference

Reversal of late septic shock with supraphysiologic doses of hydrocortisone

31 March 2020

1 reference

Plasma cortisol levels before and during "low-dose" hydrocortisone therapy and their relationship to hemodynamic improvement in patients with septic shock.

31 March 2020

1 reference

Immunologic and hemodynamic effects of "low-dose" hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study

31 March 2020

1 reference

C1-inhibitor in patients with severe sepsis and septic shock: beneficial effect on renal dysfunction

31 March 2020

1 reference

Administration of an antibody to E-selectin in patients with septic shock.

31 March 2020

1 reference

Early goal-directed therapy in the treatment of severe sepsis and septic shock

31 March 2020

1 reference

Intensive insulin therapy in critically ill patients

31 March 2020

1 reference

Effects of remote, retroactive intercessory prayer on outcomes in patients with bloodstream infection: randomised controlled trial

31 March 2020

1 reference

Sepsis and controlled clinical trials: the odyssey

31 March 2020

1 reference

Another negative clinical trial of a new agent for the treatment of sepsis: rethinking the process of developing adjuvant treatments for serious infections

31 March 2020

1 reference

New strategies for clinical trials in patients with sepsis and septic shock

31 March 2020

1 reference

Clinical trials of mediator-directed therapy in sepsis: what have we learned?

31 March 2020

1 reference

Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide

31 March 2020

1 reference

A controlled trial of HA-1A in a canine model of gram-negative septic shock.

31 March 2020

1 reference

A trial of goal-oriented hemodynamic therapy in critically ill patients. SvO2 Collaborative Group.

31 March 2020

1 reference

Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine

31 March 2020

1 reference

Dear SIRS, I'm sorry to say that I don't like you

31 March 2020

1 reference

Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome

31 March 2020

1 reference

Sepsis and mediator-directed therapy: rethinking the target populations. Mediator-directed therapy in sepsis: rethinking the target populations. Toronto, Canada, 31 October-1 November 1998

31 March 2020

1 reference

Genetic and environmental influences on premature death in adult adoptees

31 March 2020

1 reference

Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study

31 March 2020

1 reference

Association of tumor necrosis factor-2 allele with plasma tumor necrosis factor-alpha levels and mortality from septic shock

31 March 2020

1 reference

Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome

31 March 2020

1 reference

The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure

31 March 2020

1 reference

Should morbidity replace mortality as an endpoint for clinical trials in intensive care?

31 March 2020

1 reference

Charting the course of critical illness: prognostication and outcome description in the intensive care unit

31 March 2020

1 reference

Human CAP18: a novel antimicrobial lipopolysaccharide-binding protein

31 March 2020

1 reference

7 January 2021

inferred from DOI database lookup

Inhibition of endotoxin-induced activation of human monocytes by human lipoproteins

1 reference

7 January 2021

inferred from DOI database lookup

Extracorporeal treatment for septic patients: new adsorption technologies and their clinical application

1 reference

7 January 2021

inferred from DOI database lookup

Journal of the American College of Surgeons

67

180

323

W Uhl

1995

1 reference

A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock

3 January 2024

series ordinal

122

1 reference

3 January 2024

143

30

279

LB Hinshaw

1990

1 reference

3 January 2024

Identifiers

DOI

10.1038/NRD1084

1 reference

release_yfq42yyrpnfh7oids66w44x32u

6 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/yfq42yyrpnfh7oids66w44x32u

24 November 2022

mapped directly with Wikidata item

1 reference